NANBIOSIS researcher presents polymeric nanoparticle research at RANN XIV

NANBIOSIS researcher Santiago Grijalvo presented new polymeric nanoparticle strategies for nucleic acid and phytochemical delivery at RANN XIV.

Barcelona, August 2026 — Santiago Grijalvo, researcher at NANBIOSIS Unit U12, presented an oral communication at the XIV Meeting on Nucleic Acids and Nucleosides (RANN XIV), held in Barcelona on 29 August 2026.

His presentation, “A Modular PLGA Nanoplatform Integrating Antisense Oligonucleotide Delivery and Antioxidant Co-Therapy,” highlighted recent research into polymeric nanoparticles as delivery vehicles for nucleic acids and phytochemicals. The work explores the potential of these nanoplatforms to combine different therapeutic components and improve their delivery, supporting the development of advanced nanomedicine strategies.

The research was conducted in collaboration with CIBER-BBN and CIBER-NED, bringing together expertise from different fields to investigate innovative approaches for therapeutic delivery.

NANBIOSIS expertise in nucleic acid delivery

The participation of NANBIOSIS researchers at RANN XIV reflects the infrastructure’s involvement in research addressing challenges in nanomedicine, nucleic acid delivery and advanced therapeutic technologies.

The meeting brought together young researchers and experienced experts working across nucleic acid and nucleoside chemistry and biology, including structural studies, advanced therapies, molecular modelling, bioinformatics and synthetic methodologies. RANN XIV was held at the Hotel Barceló Sants in Barcelona and was organised alongside the International Round Table on Nucleosides, Nucleotides and Nucleic Acids (IRT 2026).

NANBIOSIS was also represented among the event organisers. Prof. Ramon Eritja, Scientific Director of NANBIOSIS Unit 29, and Dr. Anna Aviñó, Scientific Coordinator of Unit 29, were members of the RANN XIV and IRT 2026 Organising Committee.

Through its multidisciplinary capabilities, NANBIOSIS supports research and development in drug delivery, nucleic acids, nanomaterials and nanomedicine, helping researchers and companies advance innovative biomedical solutions from development towards preclinical applications.

Want to stay up to date?

Our newsletter, sent every three months, is what you need. We do not spam. Subscribe here.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them: